Navigation Links
Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
Date:8/24/2010

SAN DIEGO, Aug. 24 /PRNewswire/ -- Pfenex Inc. and Cedarlane today announced that they have entered into a non-exclusive distribution agreement. Cedarlane will market and distribute high value reagent proteins produced by Pfenex to researchers in Canada and the United States. Among the products initially distributed will be vaccine carrier proteins such as CRM197 and Cholera Toxin B and cell culture related growth factors including G-CSF and Interferon beta 1-b. New products which are developed by Pfenex will be added to the Cedarlane catalogue upon launch.

"We are pleased to establish this distribution relationship with Cedarlane," stated Patrick K. Lucy, Vice President, Business Development at Pfenex Inc. "Leveraging the Pfenex Expression Technology™ platform, we are now producing and making available complex reagent proteins to meet the needs of the biotech R&D and clinical development community. As Pfenex grows its reagent proteins business, we welcome the opportunity to work with world class distributors such as Cedarlane to enable placing Pfenex products in the hands of life science researchers around the world."

"CEDARLANE is proud to add Pfenex Inc. products to its extensive portfolio," said John Course, CEDARLANE Vice President. "Canadian scientists have an even greater opportunity to consolidate their ordering from a long list of high-quality suppliers of scientific reagents." Key components of the CEDARLANE mission are to provide quality products, assure the highest in customer satisfaction and respond to the dynamic needs of every research community.

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About CEDARLANE

In business since 1957 and incorporated in 1975, CEDARLANE is a 100% Canadian Corporation and a leading supplier of research reagents in North America and worldwide. The company is ISO 9001 accredited and ISO 13485 certified.

www.pfenex.com

www.cedarlanelabs.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
2. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
3. Mach 7 Technologies Establishes New Headquarters in Burlington, VT
4. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
5. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
6. FUJIFILM Establishes Medical Informatics Organization
7. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
8. Pharmaxis Establishes Named Patient Program for Bronchitol
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
11. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 2017   Divoti USA will engrave and ... standard of the latest FDA requirements, which stipulates new criteria regarding ... in need of Medical ID jewelry such as Medical ID Bracelets, ... engraved in terms of the new FDA requirements . ... Divoti offers this dark mark fiber ...
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
Breaking Medicine News(10 mins):